{"protocolSection": {"identificationModule": {"nctId": "NCT00862641", "orgStudyIdInfo": {"id": "3606-CL-3001"}, "organization": {"fullName": "Astellas Pharma Inc", "class": "INDUSTRY"}, "briefTitle": "A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease", "officialTitle": "A Phase 4, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD)."}, "statusModule": {"statusVerifiedDate": "2012-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-04"}, "primaryCompletionDateStruct": {"date": "2009-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-03-15", "studyFirstSubmitQcDate": "2009-03-15", "studyFirstPostDateStruct": {"date": "2009-03-17", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-11-15", "resultsFirstSubmitQcDate": "2010-11-15", "resultsFirstPostDateStruct": {"date": "2010-12-15", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-09-12", "lastUpdatePostDateStruct": {"date": "2012-09-18", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Astellas Pharma Inc", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study is intended to determine the safety and tolerance of regadenoson in subjects with asthma or chronic obstructive pulmonary disease."}, "conditionsModule": {"conditions": ["Asthma", "Coronary Artery Disease", "Pulmonary Disease, Chronic Obstructive"], "keywords": ["regadenoson", "CVT 3146", "asthma", "coronary artery disease", "pulmonary disease, chronic obstructive"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "DIAGNOSTIC", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 1009, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo - Asthma", "type": "PLACEBO_COMPARATOR", "description": "Matching intravenous (IV) bolus injection, subjects with Asthma", "interventionNames": ["Drug: Placebo"]}, {"label": "Regadenoson - Asthma", "type": "EXPERIMENTAL", "description": "0.4mg / 5mL intravenous bolus injection, subjects with Asthma", "interventionNames": ["Drug: Regadenoson"]}, {"label": "Placebo - COPD", "type": "PLACEBO_COMPARATOR", "description": "Matching intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)", "interventionNames": ["Drug: Placebo"]}, {"label": "Regadenoson - COPD", "type": "EXPERIMENTAL", "description": "0.4mg / 5mL intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)", "interventionNames": ["Drug: Regadenoson"]}], "interventions": [{"type": "DRUG", "name": "Regadenoson", "description": "IV", "armGroupLabels": ["Regadenoson - Asthma", "Regadenoson - COPD"], "otherNames": ["CVT3146", "Lexiscan"]}, {"type": "DRUG", "name": "Placebo", "description": "IV", "armGroupLabels": ["Placebo - Asthma", "Placebo - COPD"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percentage of Subjects Who Had a >15% Decrease in Forced Expiratory Volume in 1 Second (FEV1) at the 2-hour Postbaseline Assessment", "description": "FEV1 data was obtained by spirometry measures.", "timeFrame": "2 Hours post dose"}], "secondaryOutcomes": [{"measure": "Use of Short-acting Bronchodilators for Treatment of Symptoms After Study Drug Administration", "description": "The data represents the numbers of subjects using short acting bronchodilators at time of selected Adverse Event (AE).\n\nShort acting bronchodilators are defined as medications coded to drugs for obstructive airway disease.\n\nThe selected respiratory symptomatic AEs included the following preferred terms: dyspnoea, dyspnoea exertional, obstructive airways disorder, tachypnoea, \\& wheezing.", "timeFrame": "Within 2 Hours of study drug administration"}, {"measure": "Use of Short-acting Bronchodilators for Treatment of Symptoms After Study Drug Administration", "description": "The data represents the numbers of subjects using short acting bronchodilators at time of selected Adverse Event (AE).\n\nShort acting bronchodilators are defined as medications coded to drugs for obstructive airway disease.\n\nThe selected respiratory symptomatic AEs included the following preferred terms: dyspnoea, dyspnoea exertional, obstructive airways disorder, tachypnoea, \\& wheezing.", "timeFrame": "Within 24 Hours of study drug administration"}, {"measure": "Change From Baseline to the 2 Hour Post-dose Assessment for FEV1 Absolute Values", "description": "FEV1 data was obtained by spirometry measurements.\n\nChange from Baseline is calculated as the Hour 2 measurement minus the Baseline measurement.", "timeFrame": "Baseline and Hour 2"}, {"measure": "Change From Baseline to the 2 Hour Post-dose Assessment for FEV1 Percent Predicted", "description": "FEV1 data was obtained by spirometry measurements.\n\nChange from Baseline is calculated as the Hour 2 measurement minus the Baseline measurement.", "timeFrame": "Baseline and Hour 2"}, {"measure": "Change From Baseline to the 2 Hour Post-dose Assessment for Forced Vital Capacity (FVC)", "description": "FVC data was obtained by spirometry measurements.\n\nChange from Baseline is calculated as the Hour 2 measurement minus the Baseline measurement.", "timeFrame": "Baseline and Hour 2"}, {"measure": "Change From Baseline to the 2 Hour Post-dose Assessment for FEV1/ FVC Ratio", "description": "FEV1 and FVC data was obtained by spirometry measurements.\n\nChange from Baseline is calculated as the Hour 2 measurement minus the Baseline measurement.", "timeFrame": "Baseline and Hour 2"}, {"measure": "Change From Baseline to the 2 Hour Post-dose Assessment for Oxygen Saturation Measured by Pulse Oximetry", "description": "Change from Baseline is calculated as the Hour 2 measurement minus the Baseline measurement.", "timeFrame": "Baseline and Hour 2"}, {"measure": "Percentage of Selected Respiratory Adverse Events", "description": "The selected respiratory Adverse Events are dyspnoea, dyspnoea exertional, obstructive airways disorder, tachypnoea and wheezing.\n\nSubjects may have reported more than one type of Adverse Event.", "timeFrame": "Within 24 Hours of study drug administration"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Subject has asthma or stable chronic obstructive pulmonary disease (COPD).\n* Subject has a diagnosis of coronary artery disease (CAD) or risk factors for CAD as determined by a current medical diagnosis of at least 2 of the following conditions: Type 2 diabetes, hypertension, hypercholesterolemia, current or history of cigarette smoking (minimum 10 pack-years exposure) or obesity Body Mass Index (BMI \\> 30).\n* Subject must abstain from smoking 3 hours prior and 8 hours post study drug administration.\n* Subject must abstain from any intake of foods and beverages containing a methylated xanthine derivative (i.e. caffeine, theobromine, or methylxanthine) within 12 hours prior to study drug administration through the Follow-Up visit, as these foods may reduce the effects of regadenoson.\n* Subject is able to safely abstain from theophylline for 12 hours prior to the Day 1 visit, as determined by the Investigator\n* Asthma subject's frequency and severity of symptoms have remained unchanged within 30 days prior to study drug administration\n* Asthma subject has FEV1 \u226560% predicted\n* COPD subject has FEV1/FVC \\< 0.70\n\nExclusion Criteria:\n\n* Female subject who is pregnant, lactating or of childbearing potential who refuses to use a medically acceptable form of contraception until the Follow-Up visit is complete.\n* Subject started on a course of corticosteroids, steroid combination with long-acting Beta2-agonist (LABA) (oral or inhaled) or anticholinergic, or has undergone a change in dose of such medications \u2264 30 days prior to study drug administration (subject on a stable dose of such medications for \\> 30 days prior to study drug administration is allowed).\n* Subject started leukotriene antagonists (e.g., montelukast), cromones (e.g., cromolyn sodium) or 5-lipoxygenase antagonists (e.g. zileuton or zyflo) or has undergone a change in dose of medications in these drug classes \u2264 7 days prior to study drug administration (subject on a stable dose of these medications for \\> 7 days prior to study drug administration is allowed).\n* Subject has a history of second or third degree heart block or sinus node dysfunction unless the subject has a functioning pacemaker.\n* Subject has symptomatic hypotension (temporary and reversible conditions that no longer exist are allowed).\n* Subject is allergic or intolerant to aminophylline.\n* Subject has had a respiratory infection within 2 weeks prior to randomization.\n* Subject has had surgery within 3 months prior to randomization.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Use Central Contact", "affiliation": "Astellas Pharma Global Development", "role": "STUDY_DIRECTOR"}], "locations": [{"city": "Montgomery", "state": "Alabama", "zip": "36117", "country": "United States", "geoPoint": {"lat": 32.36681, "lon": -86.29997}}, {"city": "Anaheim", "state": "California", "zip": "92801", "country": "United States", "geoPoint": {"lat": 33.83529, "lon": -117.9145}}, {"city": "Encinitas", "state": "California", "zip": "92024", "country": "United States", "geoPoint": {"lat": 33.03699, "lon": -117.29198}}, {"city": "Fullerton", "state": "California", "zip": "92835", "country": "United States", "geoPoint": {"lat": 33.87029, "lon": -117.92534}}, {"city": "Huntington Beach", "state": "California", "zip": "92647", "country": "United States", "geoPoint": {"lat": 33.6603, "lon": -117.99923}}, {"city": "Long Beach", "state": "California", "zip": "90806", "country": "United States", "geoPoint": {"lat": 33.76696, "lon": -118.18923}}, {"city": "Mission Viejo", "state": "California", "zip": "92691", "country": "United States", "geoPoint": {"lat": 33.60002, "lon": -117.672}}, {"city": "Roseville", "state": "California", "zip": "95661", "country": "United States", "geoPoint": {"lat": 38.75212, "lon": -121.28801}}, {"city": "San Diego", "state": "California", "zip": "92120", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"city": "San Diego", "state": "California", "zip": "92123", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"city": "Santa Ana", "state": "California", "zip": "92704", "country": "United States", "geoPoint": {"lat": 33.74557, "lon": -117.86783}}, {"city": "Waterbury", "state": "Connecticut", "zip": "06708", "country": "United States", "geoPoint": {"lat": 41.55815, "lon": -73.0515}}, {"city": "Newark", "state": "Delaware", "zip": "19713", "country": "United States", "geoPoint": {"lat": 39.68372, "lon": -75.74966}}, {"city": "Wilmington", "state": "Delaware", "zip": "19807", "country": "United States", "geoPoint": {"lat": 39.74595, "lon": -75.54659}}, {"city": "Clearwater", "state": "Florida", "zip": "33756", "country": "United States", "geoPoint": {"lat": 27.96585, "lon": -82.8001}}, {"city": "Deland", "state": "Florida", "zip": "32720", "country": "United States", "geoPoint": {"lat": 29.02832, "lon": -81.30312}}, {"city": "Miami", "state": "Florida", "zip": "33173", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"city": "Trinity", "state": "Florida", "zip": "34655", "country": "United States", "geoPoint": {"lat": 28.18085, "lon": -82.68177}}, {"city": "Winter Park", "state": "Florida", "zip": "32789", "country": "United States", "geoPoint": {"lat": 28.6, "lon": -81.33924}}, {"city": "Stockbridge", "state": "Georgia", "zip": "30281", "country": "United States", "geoPoint": {"lat": 33.54428, "lon": -84.23381}}, {"city": "Aurora", "state": "Illinois", "zip": "60504", "country": "United States", "geoPoint": {"lat": 41.76058, "lon": -88.32007}}, {"city": "Topeka", "state": "Kansas", "zip": "66606", "country": "United States", "geoPoint": {"lat": 39.04833, "lon": -95.67804}}, {"city": "Shreveport", "state": "Louisiana", "zip": "71104", "country": "United States", "geoPoint": {"lat": 32.52515, "lon": -93.75018}}, {"city": "Auburn", "state": "Maine", "zip": "04210", "country": "United States", "geoPoint": {"lat": 44.09785, "lon": -70.23117}}, {"city": "No. Dartmouth", "state": "Massachusetts", "zip": "02747", "country": "United States"}, {"city": "Minneapolis", "state": "Minnesota", "zip": "55402", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"city": "Plymouth", "state": "Minnesota", "zip": "55441", "country": "United States", "geoPoint": {"lat": 45.01052, "lon": -93.45551}}, {"city": "St Louis", "state": "Missouri", "zip": "63141", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"city": "St. Louis", "state": "Missouri", "zip": "63141", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"city": "Papillion", "state": "Nebraska", "zip": "68046", "country": "United States", "geoPoint": {"lat": 41.15444, "lon": -96.04224}}, {"city": "Brick", "state": "New Jersey", "zip": "08723", "country": "United States", "geoPoint": {"lat": 40.05928, "lon": -74.13708}}, {"city": "Raleigh", "state": "North Carolina", "zip": "27607", "country": "United States", "geoPoint": {"lat": 35.7721, "lon": -78.63861}}, {"city": "Chardon", "state": "Ohio", "zip": "44024", "country": "United States", "geoPoint": {"lat": 41.61422, "lon": -81.14899}}, {"city": "Cincinnati", "state": "Ohio", "zip": "45206", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"city": "Cincinnati", "state": "Ohio", "zip": "45231", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"city": "Oklahoma", "state": "Oklahoma", "zip": "73103", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"city": "Medford", "state": "Oregon", "zip": "97504", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"city": "Upland", "state": "Pennsylvania", "zip": "19013", "country": "United States", "geoPoint": {"lat": 39.85261, "lon": -75.38269}}, {"city": "Providence", "state": "Rhode Island", "zip": "02906", "country": "United States", "geoPoint": {"lat": 41.82399, "lon": -71.41283}}, {"city": "Charleston", "state": "South Carolina", "zip": "29407", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"city": "Easley", "state": "South Carolina", "zip": "29640", "country": "United States", "geoPoint": {"lat": 34.82984, "lon": -82.60152}}, {"city": "Greenville", "state": "South Carolina", "zip": "29615", "country": "United States", "geoPoint": {"lat": 34.85262, "lon": -82.39401}}, {"city": "Spartanburg", "state": "South Carolina", "zip": "29303", "country": "United States", "geoPoint": {"lat": 34.94957, "lon": -81.93205}}, {"city": "Knoxville", "state": "Tennessee", "zip": "37920", "country": "United States", "geoPoint": {"lat": 35.96064, "lon": -83.92074}}, {"city": "Dallas", "state": "Texas", "zip": "75231", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"city": "Houston", "state": "Texas", "zip": "77074", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"city": "New Braunfels", "state": "Texas", "zip": "78130", "country": "United States", "geoPoint": {"lat": 29.703, "lon": -98.12445}}, {"city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"city": "Seattle", "state": "Washington", "zip": "98105", "country": "United States", "geoPoint": {"lat": 47.60621, "lon": -122.33207}}]}, "referencesModule": {"references": [{"pmid": "22484721", "type": "RESULT", "citation": "Prenner BM, Bukofzer S, Behm S, Feaheny K, McNutt BE. A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease. J Nucl Cardiol. 2012 Aug;19(4):681-92. doi: 10.1007/s12350-012-9547-4. Epub 2012 Apr 7."}], "seeAlsoLinks": [{"label": "Link to Prescribing information", "url": "http://www.astellas.us/docs/lexiscan.pdf"}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Placebo - Asthma", "description": "Matching intravenous (IV) bolus injection, subjects with Asthma"}, {"id": "FG001", "title": "Regadenoson - Asthma", "description": "0.4mg / 5mL intravenous bolus injection, subjects with Asthma"}, {"id": "FG002", "title": "Placebo - COPD", "description": "Matching intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)"}, {"id": "FG003", "title": "Regadenoson - COPD", "description": "0.4mg / 5mL intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "177"}, {"groupId": "FG001", "numSubjects": "360"}, {"groupId": "FG002", "numSubjects": "152"}, {"groupId": "FG003", "numSubjects": "320"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "Completed Population is equal to Safety Analysis Set (SAF)", "numSubjects": "176"}, {"groupId": "FG001", "comment": "Completed Population is equal to Safety Analysis Set (SAF)", "numSubjects": "356"}, {"groupId": "FG002", "comment": "Completed Population is equal to Safety Analysis Set (SAF)", "numSubjects": "151"}, {"groupId": "FG003", "comment": "Completed Population is equal to Safety Analysis Set (SAF)", "numSubjects": "316"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "4"}]}], "dropWithdraws": [{"type": "Randomized, but drug not received", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "4"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Placebo - Asthma", "description": "Matching intravenous (IV) bolus injection, subjects with Asthma"}, {"id": "BG001", "title": "Regadenoson - Asthma", "description": "0.4mg / 5mL intravenous bolus injection, subjects with Asthma"}, {"id": "BG002", "title": "Placebo - COPD", "description": "Matching intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)"}, {"id": "BG003", "title": "Regadenoson - COPD", "description": "0.4mg / 5mL intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)"}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "176"}, {"groupId": "BG001", "value": "356"}, {"groupId": "BG002", "value": "151"}, {"groupId": "BG003", "value": "316"}, {"groupId": "BG004", "value": "999"}]}], "measures": [{"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Between 18 and 64 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "148"}, {"groupId": "BG001", "value": "304"}, {"groupId": "BG002", "value": "95"}, {"groupId": "BG003", "value": "189"}, {"groupId": "BG004", "value": "736"}]}]}, {"title": ">=65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "28"}, {"groupId": "BG001", "value": "52"}, {"groupId": "BG002", "value": "56"}, {"groupId": "BG003", "value": "127"}, {"groupId": "BG004", "value": "263"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "115"}, {"groupId": "BG001", "value": "245"}, {"groupId": "BG002", "value": "67"}, {"groupId": "BG003", "value": "132"}, {"groupId": "BG004", "value": "559"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "61"}, {"groupId": "BG001", "value": "111"}, {"groupId": "BG002", "value": "84"}, {"groupId": "BG003", "value": "184"}, {"groupId": "BG004", "value": "440"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "128"}, {"groupId": "BG001", "value": "283"}, {"groupId": "BG002", "value": "136"}, {"groupId": "BG003", "value": "284"}, {"groupId": "BG004", "value": "831"}]}]}, {"title": "Black or African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "45"}, {"groupId": "BG001", "value": "61"}, {"groupId": "BG002", "value": "13"}, {"groupId": "BG003", "value": "22"}, {"groupId": "BG004", "value": "141"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "6"}, {"groupId": "BG004", "value": "11"}]}]}, {"title": "American Indian or Alaska Native", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "10"}]}]}, {"title": "Native Hawaiian - Other Pacific Islander", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "1"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "2"}, {"groupId": "BG004", "value": "5"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percentage of Subjects Who Had a >15% Decrease in Forced Expiratory Volume in 1 Second (FEV1) at the 2-hour Postbaseline Assessment", "description": "FEV1 data was obtained by spirometry measures.", "populationDescription": "The number of participants analyzed per arm represents Safety Analysis Set (SAF) which included all randomized subjects who received any amount of study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Subjects", "timeFrame": "2 Hours post dose", "groups": [{"id": "OG000", "title": "Placebo - Asthma", "description": "Matching intravenous (IV) bolus injection, subjects with Asthma"}, {"id": "OG001", "title": "Regadenoson - Asthma", "description": "0.4mg / 5mL intravenous bolus injection, subjects with Asthma"}, {"id": "OG002", "title": "Placebo - COPD", "description": "Matching intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)"}, {"id": "OG003", "title": "Regadenoson - COPD", "description": "0.4mg / 5mL intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "176"}, {"groupId": "OG001", "value": "356"}, {"groupId": "OG002", "value": "151"}, {"groupId": "OG003", "value": "316"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.9"}, {"groupId": "OG001", "value": "1.1"}, {"groupId": "OG002", "value": "5.4"}, {"groupId": "OG003", "value": "4.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1451", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Analysis of treatment effect was based on the Cochran-Mantel Haenszel(CMH) test stratified by investigative site. Sites with \\<15 subjects were pooled.", "ciPctValue": "95"}, {"groupIds": ["OG002", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5790", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Analysis of treatment effect was based on the CMH test stratified by investigative site. Sites with less than 15 subjects were pooled.", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Use of Short-acting Bronchodilators for Treatment of Symptoms After Study Drug Administration", "description": "The data represents the numbers of subjects using short acting bronchodilators at time of selected Adverse Event (AE).\n\nShort acting bronchodilators are defined as medications coded to drugs for obstructive airway disease.\n\nThe selected respiratory symptomatic AEs included the following preferred terms: dyspnoea, dyspnoea exertional, obstructive airways disorder, tachypnoea, \\& wheezing.", "populationDescription": "The number of participants analyzed per arm represents Safety Analysis Set (SAF) which included all randomized subjects who received any amount of study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Subjects", "timeFrame": "Within 2 Hours of study drug administration", "groups": [{"id": "OG000", "title": "Placebo - Asthma", "description": "Matching intravenous (IV) bolus injection, subjects with Asthma"}, {"id": "OG001", "title": "Regadenoson - Asthma", "description": "0.4mg / 5mL intravenous bolus injection, subjects with Asthma"}, {"id": "OG002", "title": "Placebo - COPD", "description": "Matching intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)"}, {"id": "OG003", "title": "Regadenoson - COPD", "description": "0.4mg / 5mL intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "176"}, {"groupId": "OG001", "value": "356"}, {"groupId": "OG002", "value": "151"}, {"groupId": "OG003", "value": "316"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "2"}]}]}]}, {"type": "SECONDARY", "title": "Use of Short-acting Bronchodilators for Treatment of Symptoms After Study Drug Administration", "description": "The data represents the numbers of subjects using short acting bronchodilators at time of selected Adverse Event (AE).\n\nShort acting bronchodilators are defined as medications coded to drugs for obstructive airway disease.\n\nThe selected respiratory symptomatic AEs included the following preferred terms: dyspnoea, dyspnoea exertional, obstructive airways disorder, tachypnoea, \\& wheezing.", "populationDescription": "The number of participants analyzed per arm represents Safety Analysis Set (SAF) which included all randomized subjects who received any amount of study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Subjects", "timeFrame": "Within 24 Hours of study drug administration", "groups": [{"id": "OG000", "title": "Placebo - Asthma", "description": "Matching intravenous (IV) bolus injection, subjects with Asthma"}, {"id": "OG001", "title": "Regadenoson - Asthma", "description": "0.4mg / 5mL intravenous bolus injection, subjects with Asthma"}, {"id": "OG002", "title": "Placebo - COPD", "description": "Matching intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)"}, {"id": "OG003", "title": "Regadenoson - COPD", "description": "0.4mg / 5mL intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "176"}, {"groupId": "OG001", "value": "356"}, {"groupId": "OG002", "value": "151"}, {"groupId": "OG003", "value": "316"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "5"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to the 2 Hour Post-dose Assessment for FEV1 Absolute Values", "description": "FEV1 data was obtained by spirometry measurements.\n\nChange from Baseline is calculated as the Hour 2 measurement minus the Baseline measurement.", "populationDescription": "The number of participants analyzed per arm represents Safety Analysis Set (SAF) which included all randomized subjects who received any amount of study drug. The number of participants included in the calculation for each time point is noted in the category titles, as \"N\".", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liters", "timeFrame": "Baseline and Hour 2", "groups": [{"id": "OG000", "title": "Placebo - Asthma", "description": "Matching intravenous (IV) bolus injection, subjects with Asthma"}, {"id": "OG001", "title": "Regadenoson - Asthma", "description": "0.4mg / 5mL intravenous bolus injection, subjects with Asthma"}, {"id": "OG002", "title": "Placebo - COPD", "description": "Matching intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)"}, {"id": "OG003", "title": "Regadenoson - COPD", "description": "0.4mg / 5mL intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "176"}, {"groupId": "OG001", "value": "356"}, {"groupId": "OG002", "value": "151"}, {"groupId": "OG003", "value": "316"}]}], "classes": [{"title": "Baseline (N=176; 356; 151; 316)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.41", "spread": "0.689"}, {"groupId": "OG001", "value": "2.35", "spread": "0.623"}, {"groupId": "OG002", "value": "1.70", "spread": "0.630"}, {"groupId": "OG003", "value": "1.70", "spread": "0.655"}]}]}, {"title": "Hour 2 (N=174; 351; 147; 313)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.37", "spread": "0.677"}, {"groupId": "OG001", "value": "2.33", "spread": "0.615"}, {"groupId": "OG002", "value": "1.69", "spread": "0.651"}, {"groupId": "OG003", "value": "1.70", "spread": "0.647"}]}]}, {"title": "Change at Hour 2 (N=174; 351; 147; 313)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.05", "spread": "0.160"}, {"groupId": "OG001", "value": "-0.01", "spread": "0.129"}, {"groupId": "OG002", "value": "-0.01", "spread": "0.152"}, {"groupId": "OG003", "value": "0.00", "spread": "0.159"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "P-value applies to 'Change at Hour 2'", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0029", "statisticalMethod": "ANCOVA", "ciPctValue": "95"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "P-value applies to 'Change at Hour 2'", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.6189", "statisticalMethod": "ANCOVA", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Change From Baseline to the 2 Hour Post-dose Assessment for FEV1 Percent Predicted", "description": "FEV1 data was obtained by spirometry measurements.\n\nChange from Baseline is calculated as the Hour 2 measurement minus the Baseline measurement.", "populationDescription": "The number of participants analyzed per arm represents Safety Analysis Set (SAF) which included all randomized subjects who received any amount of study drug. The number of participants included in the calculation for each row is noted in the category titles, as \"N\".", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of Predicted FEV1", "timeFrame": "Baseline and Hour 2", "groups": [{"id": "OG000", "title": "Placebo - Asthma", "description": "Matching intravenous (IV) bolus injection, subjects with Asthma"}, {"id": "OG001", "title": "Regadenoson - Asthma", "description": "0.4mg / 5mL intravenous bolus injection, subjects with Asthma"}, {"id": "OG002", "title": "Placebo - COPD", "description": "Matching intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)"}, {"id": "OG003", "title": "Regadenoson - COPD", "description": "0.4mg / 5mL intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "176"}, {"groupId": "OG001", "value": "356"}, {"groupId": "OG002", "value": "151"}, {"groupId": "OG003", "value": "316"}]}], "classes": [{"title": "Baseline (N=176; 356; 151; 316)", "categories": [{"measurements": [{"groupId": "OG000", "value": "81.34", "spread": "13.679"}, {"groupId": "OG001", "value": "80.32", "spread": "12.990"}, {"groupId": "OG002", "value": "55.67", "spread": "15.131"}, {"groupId": "OG003", "value": "55.69", "spread": "16.775"}]}]}, {"title": "Hour 2 (N=174; 351; 147; 313)", "categories": [{"measurements": [{"groupId": "OG000", "value": "79.91", "spread": "13.591"}, {"groupId": "OG001", "value": "80.11", "spread": "13.324"}, {"groupId": "OG002", "value": "54.89", "spread": "15.601"}, {"groupId": "OG003", "value": "55.61", "spread": "16.843"}]}]}, {"title": "Change at Hour 2 (N=174; 351; 147; 313)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.56", "spread": "5.368"}, {"groupId": "OG001", "value": "-0.17", "spread": "4.519"}, {"groupId": "OG002", "value": "-0.56", "spread": "4.846"}, {"groupId": "OG003", "value": "-0.06", "spread": "5.170"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "P-value applies to 'Change at Hour 2'", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0015", "statisticalMethod": "ANCOVA", "ciPctValue": "95"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "P-value applies to 'Change at Hour 2'", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4385", "statisticalMethod": "ANCOVA", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Change From Baseline to the 2 Hour Post-dose Assessment for Forced Vital Capacity (FVC)", "description": "FVC data was obtained by spirometry measurements.\n\nChange from Baseline is calculated as the Hour 2 measurement minus the Baseline measurement.", "populationDescription": "The number of participants analyzed per arm represents Safety Analysis Set (SAF) which included all randomized subjects who received any amount of study drug. The number of participants included in the calculation for each row is noted in the category titles, as \"N\".", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liters", "timeFrame": "Baseline and Hour 2", "groups": [{"id": "OG000", "title": "Placebo - Asthma", "description": "Matching intravenous (IV) bolus injection, subjects with Asthma"}, {"id": "OG001", "title": "Regadenoson - Asthma", "description": "0.4mg / 5mL intravenous bolus injection, subjects with Asthma"}, {"id": "OG002", "title": "Placebo - COPD", "description": "Matching intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)"}, {"id": "OG003", "title": "Regadenoson - COPD", "description": "0.4mg / 5mL intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "176"}, {"groupId": "OG001", "value": "356"}, {"groupId": "OG002", "value": "151"}, {"groupId": "OG003", "value": "316"}]}], "classes": [{"title": "Baseline (N=176; 356; 151; 316)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.22", "spread": "0.883"}, {"groupId": "OG001", "value": "3.16", "spread": "0.829"}, {"groupId": "OG002", "value": "2.75", "spread": "0.833"}, {"groupId": "OG003", "value": "2.83", "spread": "0.889"}]}]}, {"title": "Hour 2 (N=174; 351; 147; 313)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.17", "spread": "0.887"}, {"groupId": "OG001", "value": "3.11", "spread": "0.809"}, {"groupId": "OG002", "value": "2.70", "spread": "0.856"}, {"groupId": "OG003", "value": "2.84", "spread": "0.857"}]}]}, {"title": "Change at Hour 2 (N=174; 351; 147; 313)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.06", "spread": "0.208"}, {"groupId": "OG001", "value": "-0.03", "spread": "0.168"}, {"groupId": "OG002", "value": "-0.04", "spread": "0.230"}, {"groupId": "OG003", "value": "0.00", "spread": "0.239"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "P-value applies to 'Change at Hour 2'", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0789", "statisticalMethod": "ANCOVA", "ciPctValue": "95"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "P-value applies to 'Change at Hour 2'", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0258", "statisticalMethod": "ANCOVA", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Change From Baseline to the 2 Hour Post-dose Assessment for FEV1/ FVC Ratio", "description": "FEV1 and FVC data was obtained by spirometry measurements.\n\nChange from Baseline is calculated as the Hour 2 measurement minus the Baseline measurement.", "populationDescription": "The number of participants analyzed per arm represents Safety Analysis Set (SAF) which included all randomized subjects who received any amount of study drug. The number of participants included in the calculation for each row is noted in the category titles, as \"N\".", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of FEV1 / FVC", "timeFrame": "Baseline and Hour 2", "groups": [{"id": "OG000", "title": "Placebo - Asthma", "description": "Matching intravenous (IV) bolus injection, subjects with Asthma"}, {"id": "OG001", "title": "Regadenoson - Asthma", "description": "0.4mg / 5mL intravenous bolus injection, subjects with Asthma"}, {"id": "OG002", "title": "Placebo - COPD", "description": "Matching intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)"}, {"id": "OG003", "title": "Regadenoson - COPD", "description": "0.4mg / 5mL intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "176"}, {"groupId": "OG001", "value": "356"}, {"groupId": "OG002", "value": "151"}, {"groupId": "OG003", "value": "316"}]}], "classes": [{"title": "Baseline (N=176; 356; 151; 316)", "categories": [{"measurements": [{"groupId": "OG000", "value": "74.88", "spread": "7.510"}, {"groupId": "OG001", "value": "74.59", "spread": "7.084"}, {"groupId": "OG002", "value": "61.95", "spread": "12.684"}, {"groupId": "OG003", "value": "60.00", "spread": "13.191"}]}]}, {"title": "Hour 2 ( N=174; 351; 147; 313)", "categories": [{"measurements": [{"groupId": "OG000", "value": "75.11", "spread": "7.898"}, {"groupId": "OG001", "value": "75.09", "spread": "7.074"}, {"groupId": "OG002", "value": "62.26", "spread": "12.907"}, {"groupId": "OG003", "value": "59.72", "spread": "13.171"}]}]}, {"title": "Change at Hour 2 (N=174; 351; 147; 313)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.16", "spread": "3.329"}, {"groupId": "OG001", "value": "0.52", "spread": "2.562"}, {"groupId": "OG002", "value": "0.31", "spread": "3.177"}, {"groupId": "OG003", "value": "-0.30", "spread": "3.571"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "P-value applies to 'Change at Hour 2'", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2087", "statisticalMethod": "ANCOVA", "ciPctValue": "95"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "P-value applies to 'Change at Hour 2'", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0289", "statisticalMethod": "ANCOVA", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Change From Baseline to the 2 Hour Post-dose Assessment for Oxygen Saturation Measured by Pulse Oximetry", "description": "Change from Baseline is calculated as the Hour 2 measurement minus the Baseline measurement.", "populationDescription": "The number of participants analyzed per arm represents Safety Analysis Set (SAF) which included all randomized subjects who received any amount of study drug. The number of participants included in the calculation for each row is noted in the category titles, as \"N\".", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of Oxygen Saturation", "timeFrame": "Baseline and Hour 2", "groups": [{"id": "OG000", "title": "Placebo - Asthma", "description": "Matching intravenous (IV) bolus injection, subjects with Asthma"}, {"id": "OG001", "title": "Regadenoson - Asthma", "description": "0.4mg / 5mL intravenous bolus injection, subjects with Asthma"}, {"id": "OG002", "title": "Placebo - COPD", "description": "Matching intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)"}, {"id": "OG003", "title": "Regadenoson - COPD", "description": "0.4mg / 5mL intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "176"}, {"groupId": "OG001", "value": "356"}, {"groupId": "OG002", "value": "151"}, {"groupId": "OG003", "value": "316"}]}], "classes": [{"title": "Baseline (N=170; 350; 143; 302)", "categories": [{"measurements": [{"groupId": "OG000", "value": "96.3", "spread": "1.81"}, {"groupId": "OG001", "value": "96.3", "spread": "1.81"}, {"groupId": "OG002", "value": "94.7", "spread": "2.40"}, {"groupId": "OG003", "value": "95.0", "spread": "2.45"}]}]}, {"title": "Hour 2 (N=170; 349; 143; 299)", "categories": [{"measurements": [{"groupId": "OG000", "value": "95.9", "spread": "1.80"}, {"groupId": "OG001", "value": "96.0", "spread": "1.78"}, {"groupId": "OG002", "value": "94.2", "spread": "2.25"}, {"groupId": "OG003", "value": "94.5", "spread": "2.18"}]}]}, {"title": "Change at Hour 2 (N=170; 349; 143; 299)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.4", "spread": "1.47"}, {"groupId": "OG001", "value": "-0.4", "spread": "1.35"}, {"groupId": "OG002", "value": "-0.4", "spread": "1.42"}, {"groupId": "OG003", "value": "-0.5", "spread": "1.66"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "P-value applies to 'Change at Hour 2'\n\nP-value based on ranked analysis of covariance with treatment and investigator site as main effects and baseline value as a covariate in the model.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.9904", "statisticalMethod": "ANCOVA", "ciPctValue": "95"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "P-value applies to 'Change at Hour 2'\n\nP-value based on ranked analysis of covariance with treatment and investigator site as main effects and baseline value as a covariate in the model.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.8085", "statisticalMethod": "ANCOVA", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Percentage of Selected Respiratory Adverse Events", "description": "The selected respiratory Adverse Events are dyspnoea, dyspnoea exertional, obstructive airways disorder, tachypnoea and wheezing.\n\nSubjects may have reported more than one type of Adverse Event.", "populationDescription": "The number of participants analyzed per arm represents Safety Analysis Set (SAF) which included all randomized subjects who received any amount of study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Subjects", "timeFrame": "Within 24 Hours of study drug administration", "groups": [{"id": "OG000", "title": "Placebo - Asthma", "description": "Matching intravenous (IV) bolus injection, subjects with Asthma"}, {"id": "OG001", "title": "Regadenoson - Asthma", "description": "0.4mg / 5mL intravenous bolus injection, subjects with Asthma"}, {"id": "OG002", "title": "Placebo - COPD", "description": "Matching intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)"}, {"id": "OG003", "title": "Regadenoson - COPD", "description": "0.4mg / 5mL intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "176"}, {"groupId": "OG001", "value": "356"}, {"groupId": "OG002", "value": "151"}, {"groupId": "OG003", "value": "316"}]}], "classes": [{"title": "Dyspnoea", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.1"}, {"groupId": "OG001", "value": "10.7"}, {"groupId": "OG002", "value": "2.6"}, {"groupId": "OG003", "value": "18.0"}]}]}, {"title": "Wheezing", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.1"}, {"groupId": "OG001", "value": "3.1"}, {"groupId": "OG002", "value": "0.7"}, {"groupId": "OG003", "value": "0.9"}]}]}, {"title": "Obstructive Airways Disorder", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0.3"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Dyspnoea Exertional", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0.7"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Tachypnoea", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0.3"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Adverse Event collection began immediately following study drug administration through the follow-up visit. Serious Adverse Events occurring until 30 days after dosing were reported.", "description": "Treatment Emergent Adverse Events were defined as Adverse Events starting or worsening after starting administration of the test drug.\n\nWithin a system organ class subjects may have reported more than one type of Adverse Event.", "eventGroups": [{"id": "EG000", "title": "Placebo - Asthma", "description": "Matching intravenous (IV) bolus injection, subjects with Asthma", "seriousNumAffected": 0, "seriousNumAtRisk": 176, "otherNumAffected": 40, "otherNumAtRisk": 176}, {"id": "EG001", "title": "Regadenoson - Asthma", "description": "0.4mg / 5mL intravenous bolus injection, subjects with Asthma", "seriousNumAffected": 2, "seriousNumAtRisk": 356, "otherNumAffected": 212, "otherNumAtRisk": 356}, {"id": "EG002", "title": "Placebo - COPD", "description": "Matching intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)", "seriousNumAffected": 0, "seriousNumAtRisk": 151, "otherNumAffected": 30, "otherNumAtRisk": 151}, {"id": "EG003", "title": "Regadenoson - COPD", "description": "0.4mg / 5mL intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)", "seriousNumAffected": 4, "seriousNumAtRisk": 316, "otherNumAffected": 177, "otherNumAtRisk": 316}], "seriousEvents": [{"term": "Atrioventricular block complete", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 176}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 356}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 316}]}, {"term": "Bradycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 176}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 356}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 316}]}, {"term": "Electrocardiogram change", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 176}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 356}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 316}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 176}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 356}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 316}]}, {"term": "Rectal hemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "SAE was reported after the follow-up visit.", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 176}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 356}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 316}]}, {"term": "Amyotrophic lateral sclerosis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "SAE was reported after the follow-up visit.", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 176}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 356}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 316}]}], "otherEvents": [{"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 17, "numAtRisk": 176}, {"groupId": "EG001", "numAffected": 97, "numAtRisk": 356}, {"groupId": "EG002", "numAffected": 12, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 62, "numAtRisk": 316}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 176}, {"groupId": "EG001", "numAffected": 69, "numAtRisk": 356}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 45, "numAtRisk": 316}]}, {"term": "Dysgeusia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 13, "numAtRisk": 176}, {"groupId": "EG001", "numAffected": 33, "numAtRisk": 356}, {"groupId": "EG002", "numAffected": 6, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 29, "numAtRisk": 316}]}, {"term": "Chest discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 176}, {"groupId": "EG001", "numAffected": 44, "numAtRisk": 356}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 35, "numAtRisk": 316}]}, {"term": "Feeling hot", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 176}, {"groupId": "EG001", "numAffected": 19, "numAtRisk": 356}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 20, "numAtRisk": 316}]}, {"term": "Tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 176}, {"groupId": "EG001", "numAffected": 24, "numAtRisk": 356}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 10, "numAtRisk": 316}]}, {"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 176}, {"groupId": "EG001", "numAffected": 19, "numAtRisk": 356}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 11, "numAtRisk": 316}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 176}, {"groupId": "EG001", "numAffected": 43, "numAtRisk": 356}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 27, "numAtRisk": 316}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 176}, {"groupId": "EG001", "numAffected": 38, "numAtRisk": 356}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 57, "numAtRisk": 316}]}, {"term": "Flushing", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 176}, {"groupId": "EG001", "numAffected": 35, "numAtRisk": 356}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 37, "numAtRisk": 316}]}, {"term": "Heart rate increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 176}, {"groupId": "EG001", "numAffected": 20, "numAtRisk": 356}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG003", "numAffected": 15, "numAtRisk": 316}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript at least 30 days prior to publication to ensure that no confidential information of Sponsor is included in the document. Sponsor may delay the publication for an additional 60 days to seek patent protection."}, "pointOfContact": {"title": "Senior Medical Director, Medical Affairs", "organization": "Astellas Pharma Global Development", "email": "clinicaltrials@us.astellas.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000029424", "term": "Pulmonary Disease, Chronic Obstructive"}, {"id": "D000003324", "term": "Coronary Artery Disease"}, {"id": "D000017202", "term": "Myocardial Ischemia"}, {"id": "D000003327", "term": "Coronary Disease"}, {"id": "D000002908", "term": "Chronic Disease"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}, {"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000001161", "term": "Arteriosclerosis"}, {"id": "D000001157", "term": "Arterial Occlusive Diseases"}, {"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000020969", "term": "Disease Attributes"}, {"id": "D000010335", "term": "Pathologic Processes"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M6546", "name": "Coronary Artery Disease", "asFound": "Coronary Artery Disease", "relevance": "HIGH"}, {"id": "M11168", "name": "Lung Diseases", "asFound": "Pulmonary Disease", "relevance": "HIGH"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "asFound": "Obstructive Pulmonary Disease", "relevance": "HIGH"}, {"id": "M19506", "name": "Myocardial Ischemia", "asFound": "Coronary Artery Disease", "relevance": "HIGH"}, {"id": "M6549", "name": "Coronary Disease", "asFound": "Coronary Artery Disease", "relevance": "HIGH"}, {"id": "M23449", "name": "Pulmonary Disease, Chronic Obstructive", "asFound": "Pulmonary Disease, Chronic Obstructive", "relevance": "HIGH"}, {"id": "M10543", "name": "Ischemia", "relevance": "LOW"}, {"id": "M6147", "name": "Chronic Disease", "asFound": "Disease, Chronic", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M4469", "name": "Arteriosclerosis", "relevance": "LOW"}, {"id": "M4465", "name": "Arterial Occlusive Diseases", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}, {"id": "M22700", "name": "Disease Attributes", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "asFound": "Chronic", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000430916", "term": "Regadenoson"}], "ancestors": [{"id": "D000058908", "term": "Adenosine A2 Receptor Agonists"}, {"id": "D000058906", "term": "Purinergic P1 Receptor Agonists"}, {"id": "D000058913", "term": "Purinergic Agonists"}, {"id": "D000058905", "term": "Purinergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M227440", "name": "Regadenoson", "asFound": "Solution for infusion", "relevance": "HIGH"}, {"id": "M3595", "name": "Adenosine", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "Analg", "name": "Analgesics"}]}}, "hasResults": true}